2024
ACoP 2024, Phoenix, AZ, US
Mechanistic translational modeling versus minimal anticipated biological effect level approach to predict first-in-human dose for T-cell engagers: HPN536 case study
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Authors: Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
Development of QSP model of non-small cell lung cancer and its application to select optimal dose for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
Authors: Gaurav Bajaj (1), Alexandra Diakonova (2), Sergey Smirnov (2), Anna Roskoshnaia (2), Ivan Borisov (2), Patricia Garrido Castro (3), Nora Pencheva (3), Maria Jure-Kunkel (1), Beesan Tan (4), Tim Maiwald (4), Manish Gupta (1), Oleg Demin (5), Craig Thalhauser (1)
Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Paphos, Cyprus; (3) Genmab Utrecht, Netherlands; (4) BioNTech SE, Mainz, Germany; (5) InSysBio UK, Edinburgh, UK
Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
Authors: Gaurav Bajaj (1), Dmitry Shchelokov (2), Oleg Demin Jr (2), Homer Adams III (1), Summer Feng (1), Leonid Gibiansky (3), Saskia van der Lee (4), Anandhi Johri (1), Alexander Muik (5), Porntula Panorchan (5), Manish Gupta (1), Oleg Demin (6), Craig Thalhauser (1)
Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Limassol, Cyprus; (3) QuantPharm LLC, North Potomac, MD, USA; (4) Genmab, Utrecht, The Netherlands; (5) BioNTech SE, Mainz, Germany; (6) InSysBio UK, Edinburgh, UK
Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Authors: Evgeny Metelkin (1), Ivan Borisov (1), Sergey Smirnov (1), Oleg Demin (2), Gaurav Bajaj (3), Jordan Blum (3), Maria Jure-Kunkel (3), Beesan Tan (4), Tim Maiwald (4), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, NJ, (4) BioNTech SE, Mainz, Germany
Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Authors: Tatiana Karelina, Oleg Demin, Dmitry Gordeev, Mariia Myshkina
Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Authors: Tatiana Karelina (1), Valeriu Damian (2), Oleg Demin (3), Stepan Lerner (1), Polina Maliukova (1), Mahadevabharath Somayaji (2), Olga Ivanova (1)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) GSK, Collegeville, PA, US; (3) InSysBio UK, Edinburgh, UK
Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
Authors: Ruslan Salimgareev, Oleg Demin Jr, Oleg Demin
SITC 2024, Houston, TX, US
Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling
Authors: Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin
PAGE 2024, Rome, Italy
Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis
Authors: Oleg Demin Jr, Galina Kolesova, Oleg Demin, Dmitry Shchelokov
Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Secure and Scalable Computational Environment for Virtual Patients Simulations
Authors: Ivan Borisov, Evgeny Metelkin
ASCPT 2024 Annual Meeting, Colorado Springs, CO, US
Validation of a Quantitative Systems Pharmacology model for Chronic Hepatitis B
Authors: Galina Lebedeva (1), Alexander Stepanov (1), Veronika Musatova (2), Oleg Demin (1), Loveleena Bansal (3), Cibele V. Falkenberg (3), Valeriu Damian (3)
Affiliation: (1) InSysBio UK, Edinburgh, UK; (2) InSysBio CY, Paphos, Cyprus; (3) GSK, Collegeville, PA, US
Response to lymphocyte depleting and lymphocyte modulating therapies in different populations of patients with multiple sclerosis investigated by Quantitative Systems Pharmacology model
Authors: Tatiana Karelina, Maria Myshkina, Oleg Demin
Unraveling IL9 serum distribution patterns: insights from the CYTOCON Database
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
2023
ACoP14, National Harbor, MD, US
fIVE DB Calculator: web application for parameter calculation from in vitro data
Authors: Alexander Stepanov, Oleg Demin
Modeling of the effects of IFNγ and TNFα release on pharmacokinetics of a bispecific antibody against PD1 and CD40
Authors: Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Calculation of PD-L1 dissociation constant using available gel filtration experimental data
Authors: Ekaterina Goryacheva, Oleg Demin
fIVE DB as a tool to collect data from in vitro experiments and automatically calculate kinetic parameters: focus on impact of experimental conditions
Authors: Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
Secure and scalable computational environment for QSP modeling and simulations
Authors: Ivan Borisov, Evgeny Metelkin
Analytical approaches to optimize structure and reduce complexity of QSP models: focus on immuno-oncology
Authors: Maria Mironovich, Julia Sergienko, Oleg Demin
QSP modeling efficacy of nilotinib on pathologic proteins in Parkinson’s disease
Authors: Tatiana Karelina, Olga Ivanova, Oleg Demin
Development and Validation of a QSP Model of Synovial Sarcoma Treatment with Lete-cel: Implementation of ORR and PFS
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Dmitry Shchelokov (1), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Translational PK/RO model of tetravalent bispecific antibody CTX8371: effect of bispecific binding and multimeric complexes formation on the PD1 and PDL1 receptor occupancy
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
QSP model of neutrophils depletion during Sarilumab treatment constructed from Immune Response Template submodels
Authors: Veronika Musatova, Oleg Demin, Anna Viktorenko
SITC 2023, San Diego, CA, US
Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data
Authors: Oleg Demin (2), Sergey Smirnov (1), Alexandra Diakonova (1), Anna Roskoshnaya (1), Gaurav Bajaj (3), Homer Adams III (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro N
Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling
Authors: Oleg Demin Jr, Dmitry Shchelokov
A Quantitative Systems Pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies
Authors: Alexandra Diakonova (1), Sergey Smirnov (1), Anna Roskoshnaia (1), Ivan Borisov (1), Oleg Demin (2), Gaurav Bajaj (3), Homer Adams III (3), Maria Jure-Kunkel (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, N
Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies via mathematical modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Natalia Ramos Hernandez (3), Thomas Faitg (3), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
